PDCD1 and neoplasm: However, inhibition of IL-17A in mice bearing KRAS-mutant lung tumors or transplantable colon cancer cell lines has provided proof-of-principle that targeting IL-17A in combination with anti–PD-1 is a viable strategy for controlling tumor growth (Li et al., 2021; Liu et al., 2021; Peng et al., 2021).